AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
But with its cell therapy unit stalling and antibody-drug conjugate Trodelvy facing challenges, the company’s oncology ambitions were brought back under the spotlight during its third-quarter ...
Last year, Gilead reported what it said were promising topline results from the EVOKE-02 study of Trodelvy in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and chemo in patients ...
Later at the meeting, it will also present the results of the phase 2 EVOKE-02 study of Trodelvy in combination with MSD’s Keytruda (pembrolizumab) in first-line PD-L1-high NSCLC. The two ...
Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...
Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...
Get the full experience! Unlock access to all videos with the Unlimited Trains.com Membership.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback